Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07076303 · ClinicalTrials.gov registry record

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

A clinical trial of Glaucoma and Primary Open Angle Glaucoma, sponsored by Brian Shafer.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT07076303: Recruiting study of Glaucoma and Primary Open Angle Glaucoma, sponsored by Brian Shafer.

NCT07076303 is a study of Glaucoma and Primary Open Angle Glaucoma that is actively recruiting participants, run by Brian Shafer. The registered enrollment target is 60 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07076303, a study of Glaucoma and Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by Brian Shafer.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective Laser Trabeculoplasty (DSLT) represents a potential surgical alternative for managing IOP in patients with naive, untreated glaucoma. This study aims to evaluate the efficacy of DSLT in achieving significant IOP reduction without the need for postoperative medications. Unmet Medical Need: Overview of DSLT Direct Selective Laser Trabeculoplasty (DSLT) is an emerging technology in glaucoma management that combines laser techniques to reduce intraocular pressure (IOP). While it works off the auspices of a previous technology (SLT), the method of delivery is significantly different. Current Research Landscape Most existing studies focus on patients who have already received other forms of treatment or who have more advanced glaucoma. This creates an unmet need to evaluate how DSLT can be effectively integrated into the management of patients at the very beginning of their glaucoma journey. Understanding its efficacy in this population is crucial for establishing best practices and improving long-term outcomes. Interventional Glaucoma Management vs. Standard of Care Standard of care for newly diagnosed glaucoma typically involves medications, such as topical prostaglandin analogs, which can have side effects and may not be effective for all patients. In contrast, interventional glaucoma management-such as DSLT-offers a potentially more direct approach to lowering IOP without the need for ongoing medication. Investigating DSLT in this context could lead to a paradigm shift in how newly diagnosed patients are managed, reducing their reliance on medications and potentially improving adherence and quality of life. Conclusion Addressing this research gap will not only help

Primary Outcome

Percent Reduction in IOP from baseline at 6 months

Interventions

  • DEVICE Direct Selective Laser Trabuloplasty

Study Locations (1)

Pennsylvania

  • Shafer Vision Institute - Plymouth Meeting

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2002-03-11
Est. Completion 2026-06-01
Brian Shafer

1 total trials

What NCT07076303 shows while recruiting

NCT07076303 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (93% lower).

The record links to 3 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Direct Selective Laser Trabuloplasty is the first listed.

NCT07076303 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07076303 about?

NCT07076303 is a clinical study titled "A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients". Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective L...

What is the current status of trial NCT07076303?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2002-03-11. Estimated completion is 2026-06-01.

What conditions does trial NCT07076303 study?

This clinical trial studies the following conditions: Glaucoma, Primary Open Angle Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension.

What interventions are being tested in trial NCT07076303?

The interventions under investigation include: Direct Selective Laser Trabuloplasty (DEVICE).

Who is sponsoring clinical trial NCT07076303?

This trial is sponsored by Brian Shafer, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07076303 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07076303's enrollment target sits among peer trials

60 53rd of 92 higher than 35 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07076303, the US trial registry maintained by the National Library of Medicine. NCT07076303 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.